{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:30:16Z","timestamp":1793694616875,"version":"4.5.1"},"reference-count":61,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:00:00Z","timestamp":1793664000000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020487","name":"Break Through Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016394","name":"Ludwig Center at Harvard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016394","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Acute myeloid leukemia (AML) is prone to relapse driven by therapy-persistent residual cells. To discover specific vulnerabilities in this population, we performed genome-wide CRISPR interference screens in leukemia cells treated with multiple agents. KHSRP was the top hit, the depletion of which sensitized AML cells to therapy and substantially prolonged survival in treated AML-bearing mice. Analysis of in vivo residual disease after venetoclax\/azacitidine treatment identified downregulation of the vitamin C and uric acid transporter SLC23A1, which mediated resistance to multiple therapies. KHSRP depletion restored SLC23A1 expression by preventing its ZC3H4-mediated nuclear mRNA degradation. KHSRP depletion therefore enhanced the synergistic cytotoxicity of vitamin C and uric acid, particularly in therapy-persistent leukemia cells. Re-expression of TET2 overrode the chemosensitizing effect of KHSRP depletion in TET2-mutant leukemia, suggesting that KHSRP-linked phenotypes were related to vitamin C\u2013 and uric acid\u2013mediated TET activation. These findings suggest targeting KHSRP to enhance treatment efficacy and selectively eradicate residual AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Residual AML cells that persist following therapy have distinct biological properties compared with initial disease or overt relapse. Here, we nominate KHSRP as a target to improve therapy efficacy and exploit selective vulnerabilities of AML residual disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-26-0030","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:44:02Z","timestamp":1788378242000},"page":"878-891","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapy-Persistent Leukemia Is Selectively Vulnerable to SLC23A1 Restoration via Targeting KHSRP"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-637X","authenticated-orcid":false,"given":"Qingyu","family":"Luo","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Department of Medical Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4699-3662","authenticated-orcid":false,"given":"Karley S.","family":"Whalen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Department of Medical Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-7198","authenticated-orcid":false,"given":"Xiaowei","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 2 Department of Cancer Biology, , Boston, Massachusetts."},{"name":"3Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6774-8042","authenticated-orcid":false,"given":"Amanda L.","family":"Fortune","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Department of Medical Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Department of Medical Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0647-0342","authenticated-orcid":false,"given":"Kate","family":"Marinchev","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Department of Medical Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-8440","authenticated-orcid":false,"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02bfwt286","id-type":"ROR","asserted-by":"publisher"}],"name":"Monash University 4 Department of Epidemiology and Preventive Medicine, The School of Public Health and Preventive Medicine, , Victoria, Australia."},{"id":[{"id":"https:\/\/ror.org\/02bfwt286","id-type":"ROR","asserted-by":"publisher"}],"name":"Monash University 5 Suzhou Industrial Park Monash Research Institute of Science and Technology, , Suzhou, China."},{"name":"6Southeast University-Monash University Joint Graduate School, Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3274-3575","authenticated-orcid":false,"given":"Weiye","family":"Qian","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02bfwt286","id-type":"ROR","asserted-by":"publisher"}],"name":"Monash University 4 Department of Epidemiology and Preventive Medicine, The School of Public Health and Preventive Medicine, , Victoria, Australia."},{"name":"7State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6828-2950","authenticated-orcid":false,"given":"Evangeline G.","family":"Raulston","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Department of Medical Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8744-9617","authenticated-orcid":false,"given":"Yabing","family":"Nan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 2 Department of Cancer Biology, , Boston, Massachusetts."},{"name":"8Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-6637","authenticated-orcid":false,"given":"Christopher A.G.","family":"Booth","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Department of Medical Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2964-0963","authenticated-orcid":false,"given":"Kezhi","family":"Yan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Department of Medical Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5122-861X","authenticated-orcid":false,"given":"David E.","family":"Root","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05a0ya142","id-type":"ROR","asserted-by":"publisher"}],"name":"Broad Institute of MIT and Harvard 9 Genetic Perturbation Platform, , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-9889","authenticated-orcid":false,"given":"John G.","family":"Doench","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05a0ya142","id-type":"ROR","asserted-by":"publisher"}],"name":"Broad Institute of MIT and Harvard 9 Genetic Perturbation Platform, , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7380-0226","authenticated-orcid":false,"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jzgtq86","id-type":"ROR","asserted-by":"publisher"}],"name":"Dana-Farber Cancer Institute 1 Department of Medical Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"2026110303172076300_bib1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026110303172076300_bib2","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"2026110303172076300_bib3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026110303172076300_bib4","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026110303172076300_bib5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"2026110303172076300_bib6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","article-title":"Minimal residual disease in acute myeloid leukaemia","volume":"10","author":"Hourigan","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"2026110303172076300_bib7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"2026110303172076300_bib8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"2026110303172076300_bib9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra061808","article-title":"Cancer stem cells","volume":"355","author":"Jordan","year":"2006","journal-title":"N Engl J Med"},{"key":"2026110303172076300_bib10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"2026110303172076300_bib11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"2026110303172076300_bib12","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S2152-2650(20)30466-3","article-title":"Targeting CD123 in AML","volume":"20","author":"Lane","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026110303172076300_bib13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","article-title":"Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia","volume":"8","author":"Lane","year":"2024","journal-title":"Blood Adv"},{"key":"2026110303172076300_bib14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2026110303172076300_bib15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 function blocks aberrant self-renewal and leukemia progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"key":"2026110303172076300_bib16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s41375-023-01954-5","article-title":"Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia","volume":"37","author":"Liu","year":"2023","journal-title":"Leukemia"},{"key":"2026110303172076300_bib17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/15257770802138558","article-title":"Uric acid: the oxidant-antioxidant paradox","volume":"27","author":"Sautin","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2026110303172076300_bib18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5049\/EBP.2014.12.1.1","article-title":"Uric acid puzzle: dual role as anti-oxidantand pro-oxidant","volume":"12","author":"Kang","year":"2014","journal-title":"Electrolyte Blood Press"},{"key":"2026110303172076300_bib19","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1007\/s11010-021-04240-z","article-title":"Vitamin C for sepsis intervention: from redox biochemistry to clinical medicine","volume":"476","author":"Li","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"2026110303172076300_bib20","doi-asserted-by":"publisher","first-page":"18175","DOI":"10.1073\/pnas.2006958117","article-title":"Identification of GLUT12\/SLC2A12 as a urate transporter that regulates the blood urate level in hyperuricemia model mice","volume":"117","author":"Toyoda","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026110303172076300_bib21","doi-asserted-by":"publisher","first-page":"104976","DOI":"10.1016\/j.jbc.2023.104976","article-title":"SVCT2\/SLC23A2 is a sodium-dependent urate transporter: functional properties and practical application","volume":"299","author":"Toyoda","year":"2023","journal-title":"J Biol Chem"},{"key":"2026110303172076300_bib22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archinte.123.2.198","article-title":"Hyperuricemia complicating leukemia: treatment with allopurinol and dialysis","volume":"123","author":"Maher","year":"1969","journal-title":"Arch Intern Med"},{"key":"2026110303172076300_bib23","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1038\/s41467-018-07901-8","article-title":"Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities","volume":"9","author":"Sanson","year":"2018","journal-title":"Nat Commun"},{"key":"2026110303172076300_bib24","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1365-2141.2009.07679.x","article-title":"Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia","volume":"145","author":"Garnache-Ottou","year":"2009","journal-title":"Br J Haematol"},{"key":"2026110303172076300_bib25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov"},{"key":"2026110303172076300_bib26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjh.14146","article-title":"Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches","volume":"174","author":"Pagano","year":"2016","journal-title":"Br J Haematol"},{"key":"2026110303172076300_bib27","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"2026110303172076300_bib28","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"2026110303172076300_bib29","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1172\/JCI128571","article-title":"DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance","volume":"129","author":"Togami","year":"2019","journal-title":"J Clin Invest"},{"key":"2026110303172076300_bib30","doi-asserted-by":"publisher","first-page":"5772","DOI":"10.1093\/nar\/gkac337","article-title":"Intra-axonal translation of Khsrp mRNA slows axon regeneration by destabilizing localized mRNAs","volume":"50","author":"Patel","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2026110303172076300_bib31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s42003-022-03594-4","article-title":"KHSRP loss increases neuronal growth and synaptic transmission and alters memory consolidation through RNA stabilization","volume":"5","author":"Olguin","year":"2022","journal-title":"Commun Biol"},{"key":"2026110303172076300_bib32","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1158\/0008-5472.CAN-24-0927","article-title":"KHSRP stabilizes m6A-modified transcripts to activate FAK signaling and promote pancreatic ductal adenocarcinoma progression","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res"},{"key":"2026110303172076300_bib33","doi-asserted-by":"publisher","first-page":"eadk6989","DOI":"10.1126\/sciadv.adk6989","article-title":"Androgen receptor-regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancer","volume":"11","author":"Yang","year":"2025","journal-title":"Sci Adv"},{"key":"2026110303172076300_bib34","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2159-8290.CD-22-0601","article-title":"Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia","volume":"13","author":"Glytsou","year":"2023","journal-title":"Cancer Discov"},{"key":"2026110303172076300_bib35","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"key":"2026110303172076300_bib36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"key":"2026110303172076300_bib37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41586-024-07410-3","article-title":"Targetable leukaemia dependency on noncanonical PI3K\u03b3 signalling","volume":"630","author":"Luo","year":"2024","journal-title":"Nature"},{"key":"2026110303172076300_bib38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.str.2007.03.006","article-title":"The structure of the C-terminal KH domains of KSRP reveals a noncanonical motif important for mRNA degradation","volume":"15","author":"Garc\u00eda-Mayoral","year":"2007","journal-title":"Structure"},{"key":"2026110303172076300_bib39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.molcel.2004.05.002","article-title":"A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery","volume":"14","author":"Gherzi","year":"2004","journal-title":"Mol Cell"},{"key":"2026110303172076300_bib40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/BS9.0000000000000122","article-title":"KHSRP combines transcriptional and posttranscriptional mechanisms to regulate monocytic differentiation","volume":"4","author":"Xu","year":"2022","journal-title":"Blood Sci"},{"key":"2026110303172076300_bib41","doi-asserted-by":"publisher","first-page":"14694","DOI":"10.1038\/s41598-024-64687-0","article-title":"KHSRP has oncogenic functions and regulates the expression and alternative splicing of DNA repair genes in breast cancer MDA-MB-231 cells","volume":"14","author":"Paizula","year":"2024","journal-title":"Sci Rep"},{"key":"2026110303172076300_bib42","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1093\/hmg\/ddr430","article-title":"The X-chromosome-linked intellectual disability protein PQBP1 is a component of neuronal RNA granules and regulates the appearance of stress granules","volume":"20","author":"Kunde","year":"2011","journal-title":"Hum Mol Genet"},{"key":"2026110303172076300_bib43","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.cell.2017.12.032","article-title":"Context-dependent and disease-specific diversity in protein interactions within stress granules","volume":"172","author":"Markmiller","year":"2018","journal-title":"Cell"},{"key":"2026110303172076300_bib44","doi-asserted-by":"publisher","first-page":"110359","DOI":"10.1016\/j.isci.2024.110359","article-title":"Stress granules in cancer: adaptive dynamics and therapeutic implications","volume":"27","author":"Jia","year":"2024","journal-title":"iScience"},{"key":"2026110303172076300_bib45","first-page":"2226","article-title":"Understanding the roles of stress granule during chemotherapy for patients with malignant tumors","volume":"10","author":"Zhan","year":"2020","journal-title":"Am J Cancer Res"},{"key":"2026110303172076300_bib46","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41576-024-00712-2","article-title":"Nuclear mRNA decay: regulatory networks that control gene expression","volume":"25","author":"Rambout","year":"2024","journal-title":"Nat Rev Genet"},{"key":"2026110303172076300_bib47","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.3390\/nu5125161","article-title":"Myths, artifacts, and fatal flaws: identifying limitations and opportunities in vitamin C research","volume":"5","author":"Michels","year":"2013","journal-title":"Nutrients"},{"key":"2026110303172076300_bib48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00424-023-02792-1","article-title":"Vitamin C transporter SVCT1 serves a physiological role as a urate importer: functional analyses and in vivo investigations","volume":"475","author":"Toyoda","year":"2023","journal-title":"Pflugers Arch"},{"key":"2026110303172076300_bib49","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-140-7-200404060-00010","article-title":"Vitamin C pharmacokinetics: implications for oral and intravenous use","volume":"140","author":"Padayatty","year":"2004","journal-title":"Ann Intern Med"},{"key":"2026110303172076300_bib50","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"2026110303172076300_bib51","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"},{"key":"2026110303172076300_bib52","doi-asserted-by":"publisher","first-page":"6886","DOI":"10.1182\/bloodadvances.2023010559","article-title":"Vitamin C and D supplementation in acute myeloid leukemia","volume":"7","author":"Mouchel","year":"2023","journal-title":"Blood Adv"},{"key":"2026110303172076300_bib53","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/228868a0","article-title":"Similar functions of uric acid and ascorbate in man?","volume":"228","author":"Proctor","year":"1970","journal-title":"Nature"},{"key":"2026110303172076300_bib54","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1182\/blood.2024024769","article-title":"Ascorbate deficiency increases quiescence and self-renewal in hematopoietic stem cells and multipotent progenitors","volume":"145","author":"Comazzetto","year":"2025","journal-title":"Blood"},{"key":"2026110303172076300_bib55","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1158\/2643-3230.BCD-21-0143","article-title":"The cell type-specific 5hmC landscape and dynamics of healthy human hematopoiesis and TET2-mutant preleukemia","volume":"3","author":"Nakauchi","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2026110303172076300_bib56","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41467-017-01425-3","article-title":"KSRP specifies monocytic and granulocytic differentiation through regulating miR-129 biogenesis and RUNX1 expression","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"key":"2026110303172076300_bib57","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.molcel.2023.05.028","article-title":"ARS2 instructs early transcription termination-coupled RNA decay by recruiting ZC3H4 to nascent transcripts","volume":"83","author":"Rouvi\u00e8re","year":"2023","journal-title":"Mol Cell"},{"key":"2026110303172076300_bib58","doi-asserted-by":"publisher","first-page":"e67305","DOI":"10.7554\/eLife.67305","article-title":"ZC3H4 restricts non-coding transcription in human cells","volume":"10","author":"Estell","year":"2021","journal-title":"Elife"},{"key":"2026110303172076300_bib59","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.molcel.2023.05.029","article-title":"A restrictor complex of ZC3H4, WDR82, and ARS2 integrates with PNUTS to control unproductive transcription","volume":"83","author":"Estell","year":"2023","journal-title":"Mol Cell"},{"key":"2026110303172076300_bib60","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026110303172076300_bib61","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","article-title":"Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis","volume":"12","author":"Togami","year":"2022","journal-title":"Cancer Discov"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0030\/3826573\/bcd-26-0030.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0030\/3834817\/bcd-26-0030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/6\/878\/3844206\/bcd-26-0030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/6\/878\/3844206\/bcd-26-0030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:17:31Z","timestamp":1793693851000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/6\/878\/789640\/Therapy-Persistent-Leukemia-Is-Selectively"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":61,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,9,2]]},"published-print":{"date-parts":[[2026,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-26-0030","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.34898144","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898147","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898138","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898150","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898141","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8814749","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}